Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+early stage breast cancer

被引：0
|
作者：
O'Shaughnessy, Joyce
Oestreicher, Nina
Fulcher, Nicole
Tseng, Wan-Yu
Beeks, April
Moore, Julia
Lalla, Deepa
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P3-12-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-12-20
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+Early Stage Breast Cancer
    Vanguri, Rami S.
    Fenn, Kathleen M.
    Kearney, Matthew R.
    Wang, Qi
    Guo, Hua
    Marks, Douglas K.
    Chin, Christine
    Alcus, Claire F.
    Thompson, Julia B.
    Leu, Cheng-Shiun
    Hibshoosh, Hanina
    Kalinsky, Kevin M.
    Mathews, James C.
    Nadeem, Saad
    Hollmann, Travis J.
    Connolly, Eileen P.
    [J]. CLINICAL BREAST CANCER, 2022, 22 (06) : 538 - 546
  • [22] Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting
    Sheikh, Fareeha
    Nazir, Adil
    Yasmeen, Samia
    Badar, Farhana
    Ahmad, Usman
    Siddiqui, Neelam
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (02): : 159 - 163
  • [23] HER2-targeted PET for Patients with Breast Cancer: Scintillating Data
    Ulaner, Gary A.
    [J]. RADIOLOGY, 2024, 311 (03)
  • [24] HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
    Xu, Luying
    Xie, Yuxin
    Gou, Qiheng
    Cai, Rui
    Bao, Rong
    Huang, Yucheng
    Tang, Ruisi
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
    Lien, Huang-Chun
    Lo, Chiao
    Lee, Yi-Hsuang
    Lin, Po-Hang
    Wang, Ming-Yang
    Kuo, Wen-Hung
    Tsai, Li-Wei
    Lu, Yen-Shen
    Hu, Hsiang-Wei
    Li, Yu-Chia
    Huang, Chiun-Sheng
    [J]. BREAST CANCER RESEARCH, 2024, 26 (01)
  • [26] Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
    Kutlu, Yasin
    Cekin, Ruhper
    Aydin, Sabin Goktas
    Shbair, Abdallah T. M.
    Bilici, Ahmet
    Arici, Serdar
    Oven, Bala Basak
    Acikgoz, Ozgur
    Ozcan, Erkan
    Olmez, Omer Fatih
    Cakir, Asli
    Seker, Mesut
    [J]. CURRENT PROBLEMS IN CANCER, 2024, 50
  • [27] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constantin, Guillaume
    Roussot, Nicolas
    Ilie, Alis
    Bergeron, Anthony
    Arnould, Laurent
    Beltjens, Francoise
    Desmoulin, Isabelle
    Mayeur, Didier
    Kaderbhai, Coureche
    Hennequin, Audrey
    Jankowski, Clementine
    Padeano, Marie Martine
    Costaz, Helene
    Amet, Alix
    Coutant, Charles
    Coudert, Bruno
    Bertaut, Aurelie
    Ladoire, Sylvain
    [J]. BREAST CANCER, 2023, 30 (06) : 997 - 1007
  • [28] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Silvia Mihaela Ilie
    Nathalie Briot
    Guillaume Constantin
    Nicolas Roussot
    Alis Ilie
    Anthony Bergeron
    Laurent Arnould
    Françoise Beltjens
    Isabelle Desmoulin
    Didier Mayeur
    Courèche Kaderbhai
    Audrey Hennequin
    Clémentine Jankowski
    Marie Martine Padeano
    Helène Costaz
    Alix Amet
    Charles Coutant
    Bruno Coudert
    Aurélie Bertaut
    Sylvain Ladoire
    [J]. Breast Cancer, 2023, 30 : 997 - 1007
  • [29] Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy
    Tina J. Hieken
    Judy C. Boughey
    Amy C. Degnim
    Katrina N. Glazebrook
    Tanya L. Hoskin
    [J]. Annals of Surgical Oncology, 2022, 29 : 5383 - 5386
  • [30] Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy
    Hieken, Tina J.
    Boughey, Judy C.
    Degnim, Amy C.
    Glazebrook, Katrina N.
    Hoskin, Tanya L.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (09) : 5383 - 5386
12345